^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(11;14)

    2d
    A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=106, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Inokai (orelabrutinib)
    8d
    Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA (clinicaltrials.gov)
    P1, N=9, Recruiting, Chinese PLA General Hospital
    New P1 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • Chr t(11;14) • CD20 negative
    8d
    A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (clinicaltrials.gov)
    P1/2, N=199, Recruiting, AbbVie | N=130 --> 199
    Enrollment change • Adverse events
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • pomalidomide • surzetoclax (ABBV-453)
    9d
    Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=20, Recruiting, National Cancer Institute (NCI) | Initiation date: Sep 2026 --> May 2026
    Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Gomekli (mirdametinib)
    10d
    TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, AstraZeneca | Trial primary completion date: Jul 2028 --> Oct 2028 | Trial completion date: Jul 2028 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
    22d
    OASIS-II: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    23d
    Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Apr 2027
    Trial completion date
    |
    CCND1 (Cyclin D1) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Ibrance (palbociclib) • Imbruvica (ibrutinib)
    23d
    BELI(E)VE: Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Universitätsklinikum Hamburg-Eppendorf | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Blenrep (belantamab mafodotin-blmf)
    29d
    FOXM1 and NFκB Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma. (PubMed, Cells)
    In MCL cell lines, inhibition of FOXM1 using thiostrepton or shRNA effectively triggered apoptosis and significantly reduced cell growth...Confocal microscopy revealed that FOXM1 and p65 colocalize with each other. In conclusion, FOXM1 and NFκB work collaboratively in promoting the growth and drug resistance of MCL, and FOXM1 may be a potentially useful therapeutic target.
    Journal
    |
    CCND1 (Cyclin D1) • FOXM1 (Forkhead Box M1) • NFKBIA (NFKB Inhibitor Alpha 2) • RELA (RELA Proto-Oncogene)
    |
    Chr t(11;14)
    |
    thiostrepton (RSO-021)
    1m
    Cutaneous Involvement by Blastoid Mantle Cell Lymphoma Presenting as Cervical Abscess: A Rare Extranodal Diagnostic Challenge. (PubMed, J Cutan Pathol)
    This case highlights an unusual presentation of blastoid mantle cell lymphoma, manifesting as an abscess-like cutaneous lesion of the neck and underscores the importance of histopathologic and immunophenotypic evaluation in atypical cutaneous swellings. Early recognition, facilitated by histopathological and immunophenotypic evaluation, is critical for initiating timely and appropriate treatment in such aggressive lymphomas.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14)
    1m
    Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)
    1m
    FRONTIER: Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P2 trial
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
    |
    TP53 mutation • Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • zamtocabtagene autoleucel (MB-CART2019.1)